Application of lipid-based nanocarriers for antitubercular drug delivery: A review

Keyphrases

• Tuberculosis Treatment 100%
• Drug Delivery 100%
• Antitubercular Agents 100%
• Lipid Nanocarriers 100%
• Antimicrobial 66%
• Adverse Effects 66%
• Lipid Carriers 66%
• AIDS/HIV 33%
• Comorbid Conditions 33%
• Tuberculosis 33%
• Multidrug-resistant Tuberculosis (MDR-TB) 33%
• Drug Use 33%
• Treatment Regimen 33%
• Sustained Drug Release 33%
• Therapeutic Outcome 33%
• Anti-tuberculosis Drugs 33%
• Dose Rate 33%
• Drug Concentration 33%
• Infection Site 33%
• Prolonged Treatment 33%
• Tuberculosis Regimen 33%
• Drug Delivery Applications 33%
• Targeted Delivery 33%
• Targeted Drug Delivery 33%
• Solid Lipid Nanoparticles 33%
• Nanostructured Lipid Carriers 33%
• Liposomes 33%
• Severe Adverse Effects 33%
• Translational Development 33%
• Patient Adherence 33%
• New Drug Delivery Systems 33%
• Niosomes 33%
• Microemulsion 33%
• Low Bioavailability 33%
• Self-emulsifying Drug Delivery Systems (SEDDS) 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Drug Delivery System 100%
• Bioavailability 100%
• Nanocarrier 100%
• Infection 33%
• Antiinfective Agent 33%
• HIV 33%
• Tuberculostatic Agent 33%
• Multi-Drug-Resistant Tuberculosis 33%
• Drug Concentration 33%
• Liposome 33%
• Niosome 33%
• Targeted Drug Delivery 33%
• Solid Lipid Nanoparticle 33%
• Microemulsions 33%